<DOC>
	<DOCNO>NCT00283478</DOCNO>
	<brief_summary>To determine Iscar Quercus improve immune function quality life among patient stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Iscar Second Line Treatment Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>RAndomized pilot study supplemental Iscar combination Gemcitabine vs. Gemcitabine alone second line treatment advance non-small cell lung cancer .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>newly diagnose IIIB IV NSCLC fail one prior line chemo Karnofsky score 60 % great patient treat Gemcitabine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Advanced stage</keyword>
	<keyword>Lung cancer</keyword>
</DOC>